FCL Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
FCL Pharma
Largest movements
- Cash +€22,889
up €22,889 (+76.8%), from €29,813 to €52,702
mainly Net result for the year (+€104,960) and Other debts (+€42,500)
- Receivables within one year +€11,085
up €11,085 (+13.1%), from €84,535 to €95,620
of which Trade receivables: +€20,797
- Profit (loss) carried forward +€54,960
up €54,960 (+13.8%), from €399,429 to €454,390
- Debts after one year -€49,881
down €49,881 (-15.1%), from €329,943 to €280,063
- Other debts +€42,500
up €42,500 (+183%), from €23,200 to €65,700
- Short-term financial debts -€11,667
down €11,667 (-58.3%), from €20,000 to €8,333
- Gross operating margin +€17,937
up €17,937 (+13.7%), from €131,342 to €149,279
- Taxes +€4,712
up €4,712 (+18.8%), from €25,008 to €29,720
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €862,445 | €895,776 | +€33,331 | +3.9% |
| Fixed assets | 21/28 | €746,297 | €745,556 | -€741 | -0.1% |
| Tangible fixed assets | 22/27 | €12,912 | €12,171 | -€741 | -5.7% |
| Furniture and vehicles | 24 | €5,747 | €6,563 | +€816 | +14.2% |
| Other tangible fixed assets | 26 | €7,165 | €5,608 | -€1,557 | -21.7% |
| Financial fixed assets | 28 | €733,385 | €733,385 | = | 0.0% |
| Current assets | 29/58 | €116,149 | €150,221 | +€34,072 | +29.3% |
| Amounts receivable within one year | 40/41 | €84,535 | €95,620 | +€11,085 | +13.1% |
| Trade receivables | 40 | €74,543 | €95,340 | +€20,797 | +27.9% |
| Other amounts receivable | 41 | €9,992 | €280 | -€9,712 | -97.2% |
| Cash at bank and in hand | 54/58 | €29,813 | €52,702 | +€22,889 | +76.8% |
| Deferred charges and accrued income | 490/1 | €1,800 | €1,898 | +€98 | +5.4% |
| Total equity and liabilities | 10/49 | €862,445 | €895,776 | +€33,331 | +3.9% |
| Equity | 10/15 | €419,889 | €474,850 | +€54,960 | +13.1% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €1,860 | €1,860 | = | 0.0% |
| Distributable reserves | 133 | €1,860 | €1,860 | = | 0.0% |
| Profit (loss) carried forward | 14 | €399,429 | €454,390 | +€54,960 | +13.8% |
| Amounts payable | 17/49 | €442,556 | €420,927 | -€21,629 | -4.9% |
| Amounts payable after more than one year | 17 | €329,943 | €280,063 | -€49,881 | -15.1% |
| Financial debts | 170/4 | €329,943 | €280,063 | -€49,881 | -15.1% |
| Amounts payable within one year | 42/48 | €112,447 | €140,741 | +€28,294 | +25.2% |
| Current portion of amounts payable after more than one year | 42 | €52,407 | €49,881 | -€2,527 | -4.8% |
| Financial debts | 43 | €20,000 | €8,333 | -€11,667 | -58.3% |
| Credit institutions | 430/8 | €20,000 | €8,333 | -€11,667 | -58.3% |
| Trade debts | 44 | €766 | €256 | -€509 | -66.5% |
| Suppliers | 440/4 | €766 | €256 | -€509 | -66.5% |
| Taxes, remuneration and social security | 45 | €16,074 | €16,571 | +€497 | +3.1% |
| Taxes | 450/3 | €14,074 | €14,571 | +€497 | +3.5% |
| Remuneration and social security | 454/9 | €2,000 | €2,000 | = | 0.0% |
| Other amounts payable | 47/48 | €23,200 | €65,700 | +€42,500 | +183% |
| Accrued charges and deferred income | 492/3 | €166 | €123 | -€43 | -26.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,845 | €3,383 | +€537 | +18.9% |
| Other operating charges | 640/8 | €630 | €540 | -€90 | -14.2% |
| Gross operating margin | 9900 | €131,342 | €149,279 | +€17,937 | +13.7% |
| Operating profit (loss) | 9901 | €127,866 | €145,356 | +€17,489 | +13.7% |
| Financial income | 75/76B | €0 | €0 | +€0 | |
| Recurring financial income | 75 | €0 | €0 | +€0 | |
| Financial charges | 65/66B | €11,394 | €10,676 | -€718 | -6.3% |
| Recurring financial charges | 65 | €11,394 | €10,676 | -€718 | -6.3% |
| Profit (loss) for the period before taxes | 9903 | €116,472 | €134,680 | +€18,208 | +15.6% |
| Income taxes | 67/77 | €25,008 | €29,720 | +€4,712 | +18.8% |
| Profit (loss) for the period | 9904 | €91,465 | €104,960 | +€13,495 | +14.8% |
| Profit (loss) for the period to be appropriated | 9905 | €91,465 | €104,960 | +€13,495 | +14.8% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 31 October 2026 via checked.be.